



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GAPDH siRNA (r): sc-270067

BACKGROUND

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), also called uracil DNA glycosylase, catalyzes the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD), an important energy-yielding step in carbohydrate metabolism. While GAPDH has long been recognized as playing an integral role in glycolysis, additional functions of GAPDH include acting as a uracil DNA glycosylase, activating transcription, binding RNA and involvement in nuclear RNA export, DNA replication and DNA repair. Expression of GAPDH is upregulated in liver, lung and prostate cancers. GAPDH translocates to the nucleus during apoptosis. GAPDH complexes with neuronal proteins implicated in human neuro-degenerative disorders including the β -Amyloid precursor, Huntingtin and other triplet repeat neuronal disorder proteins.

REFERENCES

1. Meyer-Siegler, K., et al. 1991. A human nuclear uracil DNA glycosylase is the 37 kDa subunit of GAPDH. *Proc. Natl. Acad. Sci. USA* 88: 8460-8464.
2. Rondinelli, R.H., et al. 1997. Increased GAPDH gene expression in late pathological stage human prostate cancer. *Prostate Cancer Prostatic Dis.* 2: 66-72.
3. Eyschen, J., et al. 1999. Engineered glycolytic GAPDH binds the anti conformation of NAD⁺ nicotinamide but does not experience A-specific hydride transfer. *Arch. Biochem. Biophys.* 364: 219-227.
4. Sirover, M.A. 1999. New insights into an old protein: the functional diversity of mammalian GAPDH. *Biochim. Biophys. Acta* 1432: 159-184.
5. Berry, M.D., et al. 2000. GAPDH and apoptosis. *J. Neurosci. Res.* 60: 150-154.
6. Tatton, W.G., et al. 2000. GAPDH in neurodegeneration and apoptosis signaling. *J. Neural Transm. Suppl.* 60: 77-100.
7. Tarbe, N., et al. 2001. Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. *Anticancer Res.* 5: 3221-3228.
8. Mazzola, J.L., et al. 2002. Alteration of intracellular structure and function of GAPDH: a common phenotype of neurodegenerative disorders? *Neurotoxicology* 23: 603-609.

CHROMOSOMAL LOCATION

Genetic locus: *Gapdh* (rat) mapping to 4q42.

PRODUCT

GAPDH siRNA (r) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see GAPDH shRNA Plasmid (r): sc-270067-SH and GAPDH shRNA (r) Lentiviral Particles: sc-270067-V as alternate gene silencing products.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

GAPDH siRNA (r) is recommended for the inhibition of GAPDH expression in rat cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

GAPDH (0411): sc-47724 is recommended as a control antibody for monitoring of GAPDH gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker[™] Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor GAPDH gene expression knockdown using RT-PCR Primer: GAPDH (r)-PR: sc-270067-PR (20 μ l, 426 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.